利用Caco-2细胞模型评价乳源ACE抑制肽小肠吸收机制的研究进展

doi:10.7506/spkx1002-6630-201309066

食品科学 ›› 2013, Vol. 34 ›› Issue (9): 330-335.doi: 10.7506/spkx1002-6630-201309066

利用Caco-2细胞模型评价乳源ACE抑制肽小肠吸收机制的研究进展

祝倩1，郭宇星1,*，潘道东1,2

1.南京师范大学金陵女子学院，江苏南京 210097；2.宁波大学海洋学院，浙江宁波 315211

收稿日期:2012-04-06 修回日期:2013-04-10 出版日期:2013-05-15 发布日期:2013-05-07
通讯作者: 郭宇星 E-mail:yuxingguo1981@gmail.com
基金资助:
国家自然科学基金青年科学基金项目(31101314)；江苏省自然科学基金项目(BK2011787)；江苏省教育厅高校自然
科学基金项目(10KJB550003)；南京师范大学特聘教授、高层次人才科研启动基金项目(184070H2B08)

Progress in Research on Intestinal Absorption Mechanism of Milk-derived ACE Inhibitory Peptides Using Caco-2 Cell Model

ZHU Qian1，GUO Yu-xing1,*，PAN Dao-dong1,2

1. Ginling College, Nanjing Normal University, Nanjing 210097, China；
2. School of Marine Sciences, Ningbo University, Ningbo 315211, China

Received:2012-04-06 Revised:2013-04-10 Online:2013-05-15 Published:2013-05-07
Contact: GUO Yu-xing E-mail:yuxingguo1981@gmail.com

摘要/Abstract

摘要：

乳中特定的活性肽可以有效地抑制血管紧张素转化酶(ACE)的活性，起到抗高血压的作用。但是乳源ACE抑制肽由于结构不同，经口服后并不都能通过小肠黏膜进入血液循环，因此并不都具有降血压的功效，口服生物利用度也较低。本文介绍乳源ACE抑制肽的研究现状和活性评价方法，概述利用Caco-2细胞模型研究乳源ACE抑制肽在小肠中的摄入、小肠细胞中滞留代谢及小肠外排机制的研究进展，并对如何提高乳源ACE抑制肽的口服生物利用度提出展望。

关键词: Caco-2细胞模型, 乳源性ACE抑制肽, 肽吸收机制

Abstract:

The specific active peptides in milk can inhibit the activity of angiotensinⅠ-converting enzyme effectively
to execute antihypertensive effect. Due to different structures of milk-derived ACE inhibitory peptides, the peptides
are not able to pass through the intestinal mucosa into blood circulation when administered orally. Therefore, not
all ACE inhibitory peptides have the function of lowering blood pressure and a low oral bioavailability. This article
has introduced current research status and activity evaluation as well as the intestinal absorption mechanism of milkderived
ACE inhibitory peptides, which includes intestinal ingestion, metabolic activity and intestinal excretion using
Caco-2 cell model. In addition, a prospect of improving oral bioavailability of milk-derived ACE inhibitory peptides
has also been proposed.

Key words: Caco-2 cell model, milk-derived ACE inhibitory peptide, absorption mechanism of peptide

中图分类号:

TS252.1

祝倩1，郭宇星1,*，潘道东1,2. 利用Caco-2细胞模型评价乳源ACE抑制肽小肠吸收机制的研究进展[J]. 食品科学, 2013, 34(9): 330-335.

ZHU Qian1，GUO Yu-xing1,*，PAN Dao-dong1,2. Progress in Research on Intestinal Absorption Mechanism of Milk-derived ACE Inhibitory Peptides Using Caco-2 Cell Model[J]. FOOD SCIENCE, 2013, 34(9): 330-335.

参考文献

[1] 何海伦, 陈秀兰. 血管紧张素转化酶抑制肽的研究进展[J]. 中国生物工程杂志, 2004,24 (9):7-11.
[2] 曹文红，章超桦. 生物活性肽的吸收机制[J]. 药物生物技术, 2006,13(5):384~388.
[3] 郭慧青, 毛慧, 赵波等. 两种血管紧张素转化酶抑制肽作用于靶标的分子机理[J]. 食品科学, 2010, 31(23):1-5.
[4] FERREIRA S H. A bradykinin-potent iating fact or ( BPF) present in the venom of Bothrops jararaca[J]. Brit J Pharmacol, 1965, 24: 163~169.
[5] OSHIMA G, SHIMABUKURO H, NAGASAWA K. Peptide inhibitors of angiotensin-converting enzyme in digests of gelatin by bacterial collagenase [J]. Biochimicaet Biohysica Acta, 1979, 566:128-137.
[6] BLANCA H L, MARíA M C, ISIDRA R. Antihypertensive peptides: Production, bioavailability and incorporation into foods[J]. Advances in Colloid and Interface Science, 2011, 165:23-35.
[7] NAKAMURA Y, YAMAMOTO N, SAKAI K, et al. Purification and characterization of angiotensin-I converting enzyme inhibitors from sour milk[J]. J Dairy Sci, 1995, 74(8): 777-783.
[8] YAMAMOTO N., TAKANO T. Antihypertensive peptides derived from milk proteins[J]. Molecular Nutrition and Food Research, 1999, 43(3):159-164.
[9] YAMAMOTO N, AKINO A, TAKANO T. Purification and specificity of a cell-wall associated proteinase from Lactobacillus helveticus CP790[J]. Journal of Biochemistry, 1993, 114: 740-745.
[10] LAPOINTE J F, GAUTHIER S F, POULIOT Y, et al. Selective Separation of Cationic Peptides From a Tryptic Hydrolysate of β-Lactoglobulin by Electrofiltration[DB/OL]. (2006) www.interscience.wiley.com.
[11] MAVAYAMAS S，SUZUKI H. A peptide inhibitor of angiotensin converting enzyme by synthetic petides of human of casein［J］. Agric Biolchem, 2002, 46( 5) : 1393.
[12] 季闽春, 王永铭, 陈斌艳. 血管紧张素转化酶抑制剂的皮肤不良反应[J]. 中国临床药理学杂志, 1996, 12: 112- 114.
[13] 许金光,杨智超,刘长江. 血管紧张素转化酶（ACE）抑制肽的研究进展[J]. 食品工业科技, 2011, 32(5):425-427.
[14] 管骁，彭剑秋，金周筠,等.食源性血管紧张素转化酶抑制肽的研究[J].食品与发酵工业, 2011, 37( 7 ):135-141.
[15] SHAH P, JOGANI V, BAGCHI T, et al. Role of Caco-2 cell monolayers in prediction of intestinal drug absorption[J]. Biotechnol Prog, 2006, 22:186－198.
[16] ARTURSSON P , PALM K, LUTHMAN K. Caco2 monolayers in experimental and theoretical predictions of drug transport[J] . Advanced Drug Delivery Reviews , 1996 , 22 : 67-84.
[17] 关溯, 综述, 陈孝. Caco-2细胞模型---药物吸收研究的有效“工具”[J]. 中国药理学通报, 2004 , 20( 6) : 609-614.
[18] 孙勇兵,孙进,何仲贵. 小肠寡肽转运蛋白及其在提高药物口服吸收中的应用[J]. 中国新药与临床杂志, 2006, 25(10):776-782.
[19] SATAKE M, ENJOH M, NAKAMURA Y, et al. Transepithelial transport of the bioactive tripeptide Val-Pro-Pro, in human intestinal Caco-2 cell monolayers[J]. Bioscience Biotechnology and Biochemistry, 2002, 66, 378-384.
[20] 刘冬, 孙海燕, 雷林,等. 降血压肽 Val-Leu-Pro-Val-Pro 在 Caco-2 细胞模型中的吸收机制[J]. 营养学报, 2008,30(4):354-362.
[21] PAPPENHEIMER JR, DAHL C E, KARNOVSKY M L, et al. Intestinal absorption and excretion of octapeptides composed of D-amino acids[J]. Proc.Natl.Acad.Sci, 1994, 91:1942-1945.
[22] ADSON A, RAUB T J, BURTON P S, et al. Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers[J]. Pharm. Sci, 1994,83:1529-1536.
[23] SHIMIZU M, TSUNOGAI M, ARAI S. Transepithelial transport of oligopeptides in the human intestinal cell caco-2[J]. Peptides, 1997, 18:681-687.
[24] ANA Q, ALBERTO D, MIGUEL A. et al. Bioavailability of the antihypertensive peptide LHLPLP: Transepithelial flux of HLPLP[J]. International Dairy Journal, 2008, (18):279–286.
[25] 廖晓慧, 孙海燕, 彭光华,等. Caco-2细胞模型及其在食品营养物质吸收研究中的新进展[J]. 农产品加工学刊, 2007, 2:37-40.
[26] RIEKO A, YUKITAKA K, MOTOHIRO S, et al. Relationships between structure and high-throughput screening permeability of peptide derivatives and related compounds with artificial membranes: application to prediction of Caco-2 cell permeability[J]. Bioorganic & Medicinal Chemistry, 2004, (12): 257–264.
[27] VERMEIRSSEN V, DEPLANCKE B, TAPPENDEN K A, et al. Intestinal Transport of the Lactokinin
Ala-Leu-Pro-Met-His-Ile-Arg through a Caco-2 Bbe Monolayer[J]. Journal of Peptide Science , 2002, 8: 95–100.
[28] 卢智玲, 冯怡, 徐德生,等. Caco-2细胞模型在中药口服吸收及机制研究中的应用[J]. 中草药, 2006, 37(4):616-619.
[29] 郑慧娜,章超桦,吉宏武. 马氏珠母贝高F值寡肽在Caco-2 细胞中吸收的初步研究[J]. 食品与生物技术学报, 2011,30(4):613-617.
[30] 杨超，尹宗宁. 提高酶和多肽类药物口服吸收方法及机制的研究进展[J]. 中国新药杂志, 2006,15(12):945-948.

利用Caco-2细胞模型评价乳源ACE抑制肽小肠吸收机制的研究进展

Progress in Research on Intestinal Absorption Mechanism of Milk-derived ACE Inhibitory Peptides Using Caco-2 Cell Model

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 3

编辑推荐

Metrics

本文评价

[1]	雷激，黄承钰. 体外消化/Caco-2细胞模型分析发酵对面粉铁生物利用率的影响[J]. 食品科学, 2017, 38(16): 99-103.
[2]	高锦锦，郭宇星，潘道东. Caco-2细胞模型用于乳源ACE抑制肽LL、LPEW的小肠吸收研究[J]. 食品科学, 2017, 38(11): 214-219.
[3]	王晓倩，张艳芳，王倩，高晓梦，李春川，李敬，吴薇，董平，梁兴国. 基于Caco-2细胞的外源核酸吸收模型的建立及其吸收机制[J]. 食品科学, 2016, 37(23): 236-241.